

Richter and Mithra signed a license and supply agreement for commercialization of Estelle[®], a novel oral contraceptive

Budapest, Hungary – Liège, Belgium – 12 September 2018 – Gedeon Richter Plc. (hereinafter: “*Richter*”) and Mithra Pharmaceuticals (hereinafter: “*Mithra*”) today announced that they have entered into a license and supply agreement to commercialize Estelle[®], a combined oral contraceptive, containing 15 mg estetrol (E4) / 3 mg drospirenone. Richter is going to commercialize the product under a different brand name. The product is considered a novel oral contraceptive with natural, native estrogen acting selectively in tissues combined with drospirenone’s non contraceptive benefits. The geographic scope of the agreement covers Europe and Russia.

Under the terms of the agreement Richter shall make upon signature of the contract an upfront payment totaling EUR 35 million. Additional milestone payments amounting to EUR 20 million shall be made depending on the progress of the regulatory process of the product. Besides, further sales related royalties will become payable to Mithra subsequent to the launch of the product. Moreover, Mithra will receive guaranteed annual recurring revenues based on minimum annual quantities (MAQ), in addition to tiered royalties on net sales.

“Broadening our core Women’s Healthcare portfolio remains a paramount objective of Richter’s strategy aiming towards the improvement of the quality of life of the female population in all age groups. This agreement fits into this endeavour and we look forward to a successful cooperation with Mithra in the commercialization of a novel oral contraceptive,” stated Gábor Orbán, Chief Executive Officer of Gedeon Richter Plc.

“We are very pleased to have agreed terms with Richter for the commercialization of our next generation oral contraceptive product candidate Estelle[®] in Europe and Russia. This is by far the biggest contract in Mithra’s history. As an undisputed leader in Women’s Health, with a rapidly expanding direct presence in Western Europe, we are convinced that Richter is the best possible partner for Estelle[®] in this important geography. Also, today’s news further reinforces the important potential we see with regard to a US partnership, given that the US oral contraceptive market is valued at double the size of the European one. We are looking forward to a fruitful and long-term collaboration with the Richter team,” added François Fornieri CEO of Mithra.

About Estelle[®]

Estelle[®] is Mithra’s novel oral contraceptive product candidate composed of 15 mg estetrol (E4), its unique native estrogen and 3 mg drospirenone. The *E4 Freedom* studies are open-label single arm trials to assess the safety and efficacy of Estelle[®] in over 1,550 participants in Europe/Russia and approximately 2,000 participants in the US/Canada, over a period of 13 cycles. Mithra recently announced positive top-line results for its pivotal EU/Russia Phase III study, with the results of the US/Canada study to follow in Q1 2019.

About Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalisation of EUR 4.1 billion (USD 4.9 billion) by the end of 2017, Richter's consolidated sales were approximately EUR 1.4 billion (USD 1.6 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's healthcare field worldwide. Richter is also active in biosimilar product development.

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women's Health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates – a fifth generation oral contraceptive Estelle[®] and next-generation hormone therapy Donesta[®] - are built on Mithra's unique natural estrogen platform, E4 (estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

For more information:

Richter:

Investors:

Katalin Ördög: +36 1 431 5680

Media:

Zsuzsa Beke: +36 1 431 4888

Mithra:

Investors:

François Fornieri (CEO): +32 (0)477 96 17 74

Jean-Manuel Fontaine (PRO): +32 (0)476 96 54 59

Media:

Jean-Manuel Fontaine (PRO) +32 (0)476 96 54 59